Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

This study will enroll 104 patients to one of three treatment arms. The study is open to patients relapsing with refractory Multiple Myeloma who have: * received 3 prior lines of therapy * exposed to each of these 3 drug classes: * IMiD * proteasome inhibitors, and * anti-CD38 monoclonal antibody * relapsed and refractory are defined using the IMWG criteria: * disease that is non-responsive while on salvage therapy or progresses within 60 days of last therapy in patients who have achieved minimal response or better at some point previously to then progressing in their disease course.